| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/24/2005 | WO2004113335A3 Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| 03/24/2005 | WO2004112801A3 Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
| 03/24/2005 | WO2004106343A3 Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids |
| 03/24/2005 | WO2004087075A3 Compositions and methods for treating cancer |
| 03/24/2005 | WO2004083240A3 Regulation of gene expression |
| 03/24/2005 | WO2004075834A3 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 03/24/2005 | WO2004068931A3 Amphiregulin antibodies and their use to treat cancer and psoriasis |
| 03/24/2005 | WO2004040302A8 REGULATION OF INTERACTION BETWEEN RAPL AND Rap1 |
| 03/24/2005 | WO2004022699A3 Liquid stable composition of oxazaphosphorine with mesna |
| 03/24/2005 | WO2004004632A8 Flavone derivatives as inhibitors of cyclin-dependent kinases |
| 03/24/2005 | WO2004000204A3 Labelled somatostatin analogs backbone cyclized through metal complexation |
| 03/24/2005 | WO2003105875A8 Immunostimulator having antineoplastic action and method for producing said immunostimulator |
| 03/24/2005 | WO2003103478A3 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs |
| 03/24/2005 | WO2003090687A9 Using heat shock proteins to increase immune response |
| 03/24/2005 | WO2003045973A8 Peptides with growth inhibitory action |
| 03/24/2005 | WO2002092759A9 Molecules for disease detection and treatment |
| 03/24/2005 | WO2002058450A3 Regulation of cell growth by muc1 |
| 03/24/2005 | US20050065335 inhibiting complexation of intercalating molecules with polynucleotides; using modified xanthine molecules as a binding agent; drug delivery system for compounds that have low solubility in aqueous media, including anti-neoplastic agents |
| 03/24/2005 | US20050065327 Immunoglobulin specific to interleukin-13 (IL-13) for use in prevention and treatment of asthma, fibrosis, skin and cell proliferative disorders |
| 03/24/2005 | US20050065213 Anticancer agents; endometriosis; psoriasis; vision defects |
| 03/24/2005 | US20050065205 Administering protein kinase C activator such as macrocyclic lactone; mixture with enzyme inhibitor and carrier |
| 03/24/2005 | US20050065195 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 03/24/2005 | US20050065180 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue |
| 03/24/2005 | US20050065171 Therapy, prevention leukemia; antitumor agents |
| 03/24/2005 | US20050065169 Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
| 03/24/2005 | US20050065167 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents |
| 03/24/2005 | US20050065165 Method of treating certain cancers using an estrogen agonist/antagonist |
| 03/24/2005 | US20050065148 Dipeptidyl peptidase inhibitors |
| 03/24/2005 | US20050065135 Contraceptives; side effect reduction; antitumor, anticancer agents |
| 03/24/2005 | US20050065133 Synergistic mixture; bone disorders; osteoporosis ; anticancer agents; obesity |
| 03/24/2005 | US20050065130 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a cyclooxgenase-2 inhibitor |
| 03/24/2005 | US20050065127 Bone disorders; anticarcinogenic agents |
| 03/24/2005 | US20050065126 Synergistic mixture; osteoporosis therapy; bone disorders; anticancer agents; obesity |
| 03/24/2005 | US20050065123 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 |
| 03/24/2005 | US20050065118 Compound containing 1,3,4-thiadiazole group; anticancer agents; autoimmune disease; antidiabetic agents |
| 03/24/2005 | US20050065117 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bisphosphonate |
| 03/24/2005 | US20050065114 Antitumor, anticancer agents; viricides; bactericides; fungicides; immunology stimulants |
| 03/24/2005 | US20050065112 Antiproliferative agents; low toxicity; psoriasis; antitumor agents; rheumatic arthritis; gastrointestinal disorders; antiinflamamtory agents |
| 03/24/2005 | US20050065111 Concurrent administering cancer drug and glucan; synergistic mixture |
| 03/24/2005 | US20050065110 Synergistic mixture; antioxidant; cardiovascular disorders; antidiabetic agents |
| 03/24/2005 | US20050065107 Plasmids suitable for IL-2 expression |
| 03/24/2005 | US20050065097 Liver disorders; antiarrhythmia agents; anticancer agents; astaxanthin |
| 03/24/2005 | US20050065093 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/24/2005 | US20050065088 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and parathyroid hormone |
| 03/24/2005 | US20050065087 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a bone morphogenetic protein |
| 03/24/2005 | US20050064593 Expression vector comprising breast cancer gene (BCL-2) nucleotide sequences for use as tool in treatment, diagnosis and prevention of cell proliferative disorders |
| 03/24/2005 | US20050064586 Somatic cell derived embryonic stem cells and its differentiated cells |
| 03/24/2005 | US20050064572 Lipid kinase |
| 03/24/2005 | US20050064534 Using microscopic systems to monitoring f-actin and myosin activity in cells; monitoring biopolymer transfer between membrane walls |
| 03/24/2005 | US20050064530 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 03/24/2005 | US20050064522 EG-VEGF nucleic acids and polypeptides and methods of use |
| 03/24/2005 | US20050064493 Antibodies specific for vascular endothelial growth factor-B and DNA coding therefor |
| 03/24/2005 | US20050064491 Transport protein for use as tool in identifying modulator for treatment of sleep, nervous suystem, anixety, eating, cardiovascular and pain disordere |
| 03/24/2005 | US20050064475 Using type II membrane glycoprotein (4F2hc) as tool in identifying modulator which inhibit transcription in tumor cells; gene expresion inhibition and antitumors agents |
| 03/24/2005 | US20050064458 Nucleotide sequences coding membrane protein for use in diagnosis, prevention and treatnment of cell proliferative, nervous system, metabolic and inflammatory disorders |
| 03/24/2005 | US20050064445 Serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 03/24/2005 | US20050064440 Using single nucleotide polymorphism in contactin-2 (CNTN-2) and kinesin-7 (CENP-E) genes as diagnostic indicators of cell proliferative disorders; antitumor agents; ribozymes and tumor treatment; RNA interference |
| 03/24/2005 | US20050064413 Oncogenic protein for use in diagnosis, prevention and treatment of cell proliferative disorders of nervous ystem |
| 03/24/2005 | US20050064412 Using methylation profile of heparan sulfate D-glucosaminyl 3-0-sulfotransferase gene sequences as diagnostic/prognostic indicators of mamary gland cell proliferative disorders |
| 03/24/2005 | US20050064411 Diagnostic probe for identifying ubiquitin ligase (NEDl-1) profile for use as diagnostic and prognostic indicator of cell proliferative disorders of nervous system |
| 03/24/2005 | US20050064407 Bcl-2 dnazymes |
| 03/24/2005 | US20050064404 Regulation of human serotonin-like g protein-coupled receptor |
| 03/24/2005 | US20050064039 Novel microsphere and method for production thereof |
| 03/24/2005 | US20050064028 Pharmaceutical compositions containing plasma protein |
| 03/24/2005 | US20050064027 Prolonged gastric retention time due to bioadhesion (which may be polymers, metal oxides, or ligands for specific mucosal components); macrospheres for delivery of acyclovir for example |
| 03/24/2005 | US20050063995 mammalian tumor cells having been treated ex vivo by stressing with an oxidative environment such as ozone or oxygen and UV light simultaneously, to render the tumor cells effective to elicit an immune response to a melanoma, colon carcinoma or breast cancer tumor |
| 03/24/2005 | US20050063993 For treatment of cancer/tumors/fungal/viral infections; tumor associated antigens; genetic engineering |
| 03/24/2005 | US20050063992 administering to a patient 2-methylene-19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3 and an estrogen, or a salt or prodrug for treating senile osteoporosis, postmenopausal osteoporosis, bone fracture, bone graft, breast cancer, prostate cancer, obesity, osteopenia, muscle damage or sarcopenia |
| 03/24/2005 | US20050063977 Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (SCLC) |
| 03/24/2005 | US20050063971 Monoclonal or humanized antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, polypeptide fragment, polynucleotide or antibody |
| 03/24/2005 | US20050063970 An immunomolecule containing a soluble human Major Histocompatibility Complex class I effector domain linked to an antibody targeting domain; immunotherapy; anticarcinogenic agents |
| 03/24/2005 | US20050063969 Assay |
| 03/24/2005 | US20050063954 Recombinant reovirus for treating a Ras-mediated proliferative disorder such as tumors |
| 03/24/2005 | US20050063952 Immunogenic CEA |
| 03/24/2005 | US20050063947 Method for treating cancer in humans |
| 03/24/2005 | US20050063943 Conjugated of hydroxyalkyl starch and an active agent |
| 03/24/2005 | US20050063905 Administering a RADIONUCLIDE COMPLEXED WITH A CHELATING AGENT SUCH AS MACROCYCLIC AMINOPHOSPHONIC ACID, or tetraazacyclododecanetetramethylenephosphonic acid (DOTMP); polycythemia vera, macroglobulinemia (Waldenstrom syndrome), megakaryocytic myelosis, malignant histiocytosis |
| 03/24/2005 | DE102004041612A1 Extraction of carotene, Vitamin E and other minor components from natural oils and fats, for use in pharmaceuticals and food products, involves extraction of a concentrate with supercritical fluid, preferably carbon dioxide |
| 03/24/2005 | CA2788502A1 Non-peptide agonists and antagonists of adrenomedullin and gastric releasing peptide |
| 03/24/2005 | CA2578375A1 Vaccine immunotherapy for immune suppressed patients |
| 03/24/2005 | CA2541100A1 Quinazoline derivatives |
| 03/24/2005 | CA2539049A1 Quinazoline derivatives |
| 03/24/2005 | CA2539024A1 Quinazoline derivatives as antitumor agents |
| 03/24/2005 | CA2539022A1 Quinazoline derivatives as tyrosine kinase inhibitors |
| 03/24/2005 | CA2539000A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | CA2538910A1 Use of known active ingredients as radical scavengers |
| 03/24/2005 | CA2538883A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 03/24/2005 | CA2538829A1 Ceratamines a and b, and analogues, syntheses and pharmaceutical compositions thereof |
| 03/24/2005 | CA2538434A1 Novel indolopyrrolocarbazole derivative with antitumor activity |
| 03/24/2005 | CA2538429A1 Antibacterial drug for propionibacterium acnes |
| 03/24/2005 | CA2538073A1 Formulations and methods for treating breast cancer with morinda citrifolia and methylsulfonymethane |
| 03/24/2005 | CA2537931A1 Multi-antigen vectors for melanoma |
| 03/23/2005 | EP1516932A1 Poxvirus with targeted infection specificity |
| 03/23/2005 | EP1516881A2 Composition and method for modulating dendritic Cell-T cell interaction |
| 03/23/2005 | EP1516876A1 Mediators of hedgehog signalling pathways, compositions and uses related thereto |
| 03/23/2005 | EP1516625A1 Uses of neuronal channels-forming pannexins for therapy and diagnosis in mammals |
| 03/23/2005 | EP1516621A2 Use of pyrazoline derivatives in the preparation of a medicament for the prevention and/or treatment of cell proliferation diseases |
| 03/23/2005 | EP1516620A1 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor |
| 03/23/2005 | EP1516597A1 Drug eluting stent |
| 03/23/2005 | EP1516185A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |